Login to Your Account

Innovent adds home-grown IDO candidate in $457M SIOC deal

By Shannon Ellis
Staff Writer

Tuesday, September 5, 2017

SHANGHAI – Innovent Biologics Inc., of Suzhou, has acquired the global rights for a preclinical indoleamine 2,3-dioxygenase (IDO) inhibitor discovered by the Shanghai Institute of Organic Chemistry.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription